Dexcom (DXCM) Net Equity Issued and Repurchased (2010 - 2026)

Dexcom (DXCM) has reported Net Equity Issued and Repurchased for 17 consecutive years, with $12.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 10.56% year-over-year to $12.7 million in Q1 2026; TTM through Jun 2026 was $26.6 million, a 8.28% decrease from a year earlier, with the FY2025 full-year figure at $28.1 million, changed 0.35% from the prior year.
• Net Equity Issued and Repurchased was $12.7 million for Q1 2026 at Dexcom, down from $13.9 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $14.8 million in Q3 2024 and troughed at $10.1 million in Q1 2022.
• A 5-year average of $13.1 million and a median of $13.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased climbed 21.78% in 2023 and retreated 10.56% in 2026, its largest moves.
• Over 5 years, Net Equity Issued and Repurchased stood at $12.4 million in 2022, then grew by 15.32% to $14.3 million in 2023, then grew by 3.5% to $14.8 million in 2024, then dropped by 6.08% to $13.9 million in 2025, then slipped by 8.63% to $12.7 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $12.7 million (Q1 2026), $13.9 million (Q3 2025), and $14.2 million (Q1 2025), per Business Quant data.